Insmed Incorporated (NASDAQ:INSM) Stock Holdings Trimmed by GW&K Investment Management LLC

GW&K Investment Management LLC lowered its position in shares of Insmed Incorporated (NASDAQ:INSM) by 1.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,135,393 shares of the biopharmaceutical company’s stock after selling 18,122 shares during the quarter. GW&K Investment Management LLC’s holdings in Insmed were worth $78,387,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of INSM. V Square Quantitative Management LLC increased its holdings in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 248 shares during the last quarter. Spire Wealth Management bought a new position in Insmed during the fourth quarter worth $47,000. Venturi Wealth Management LLC acquired a new position in Insmed in the fourth quarter worth $86,000. Quantbot Technologies LP bought a new stake in Insmed during the third quarter valued at $133,000. Finally, Avior Wealth Management LLC acquired a new stake in shares of Insmed during the fourth quarter worth $157,000.

Analyst Ratings Changes

INSM has been the subject of several research reports. Wells Fargo & Company lifted their price target on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 target price on shares of Insmed in a report on Friday, February 21st. Royal Bank of Canada began coverage on Insmed in a report on Tuesday. They issued an “outperform” rating and a $100.00 price target on the stock. Finally, Stifel Nicolaus reduced their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $91.60.

Insider Activity at Insmed

In other news, CFO Sara Bonstein sold 18,322 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the completion of the transaction, the chief financial officer now owns 118,863 shares in the company, valued at approximately $9,545,887.53. This trade represents a 13.36 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Martina M.D. Flammer sold 3,344 shares of Insmed stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the completion of the transaction, the insider now directly owns 102,766 shares in the company, valued at $6,773,307.06. This represents a 3.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 532,207 shares of company stock worth $41,400,465 over the last quarter. 4.60% of the stock is currently owned by company insiders.

Insmed Price Performance

Shares of INSM opened at $79.05 on Friday. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91. The stock’s fifty day moving average is $74.66 and its 200-day moving average is $73.73. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a market capitalization of $14.31 billion, a price-to-earnings ratio of -14.14 and a beta of 1.11.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Equities analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.